Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCENTAGE-B

83.600
+0.4500.54%
Volume:5.06M
Turnover:413.73M
Market Cap:31.10B
PE:-57.01
High:83.850
Open:83.850
Low:80.000
Close:83.150
Loading ...

Company Profile

Company Name:
ASCENTAGE-B
Exchange:
SEHK
Establishment Date:
2009
Employees:
567
Office Location:
Suzhou Industrial Park,68 Xinqing Road,Suzhou,Jiangsu Province,China
Zip Code:
215000
Fax:
- -
Introduction:
Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.

Directors

Name
Position
Dajun Yang
Chairman, Chief Executive Officer and Director
Changqing Ye
Director
David Sidransky
Director
Debra Yu
Director
Marc E. Lippman
Director
Marina S. Bozilenko
Director
Shaomeng Wang
Director
Simon Dazhong Lu
Director
Wei Ren
Director

Shareholders

Name
Position
Dajun Yang
Chairman, Chief Executive Officer and Director
Eric Huang
Senior Vice President of Global Corporate Development and Finance
Thomas J. Knapp
Senior Vice President, General Counsel
Veet Misra
Chief Financial Officer
Jin Cao
Head of Finance
Raymond Jeffrey Kmetz
Chief Business Officer
Yifan Zhai
Chief Medical Officer